Login to Your Account



Corcept Pads Coffers with $30M Synthetic Royalty Deal

By Marie Powers
Staff Writer

Thursday, August 9, 2012
Fresh from a public offering that raised $46 million in working capital, Corcept Therapeutics Inc. sold a synthetic capped royalty on future sales of Korlym (mifepristone) and its next-generation GR-II antagonists to BioPharma Secured Debt Fund II, an investment fund managed by Pharmakon Advisors.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription